Detailed Narrative
Q1 FY27 Financial Performance Overview
Sai Parenterals Limited reported consolidated total revenue of Rs. 182 crores for Q1 FY27, a sequential decline from Rs. 201 crores in Q4 FY26. Despite this, gross profit improved to Rs. 76 crores, with the gross margin expanding by 370 basis points to 41.8% from 38.1% in the preceding quarter. Consolidated EBITDA stood at Rs. 27 crores, with the EBITDA margin improving by 50 basis points to 14.9% from 14.4%. However, Profit After Tax (PAT) saw a sequential decline to Rs. 8 crores (4.3% margin) from Rs. 13.2 crores in Q4 FY26, attributed to a lower revenue base and a normalized tax charge.
Strategic Shift in Capacity Expansion and Saicriti Acquisition
The Board approved a significant redeployment of IPO proceeds, allocating Rs. 83.83 crores for capacity expansion towards acquiring a 60% equity stake in Saicriti Pharma Private Limited. This strategic shift was necessitated by regulatory changes in Hyderabad (HILTP policy) and physical constraints at existing sites, which prevented upgrades. The acquisition of Saicriti, a company already constructing an EU-GMP and USFDA compliant injectable facility, is expected to deliver 47% more injectable capacity and includes an existing domestic critical care franchise of Rs. 52 crores. The total project cost for Saicriti is estimated at Rs. 215 crores, with Sai Parenterals contributing Rs. 83.83 crores.
Enhancement of R&D Capabilities through Prathyak Acquisition
In a move to bolster its research and development capabilities, Sai Parenterals plans to acquire a 60% equity stake in Prathyak Laboratories Private Limited for Rs. 15 crores. This acquisition, expected to complete by September 30, 2026, will provide an established R&D center in Genome Valley, Hyderabad, with 65 personnel, including 28 research scientists, and a pipeline of 150 SKUs across 86 molecules. This inorganic approach is expected to accelerate product development by bypassing the construction cycle and the need to assemble a new scientific team, allowing immediate commencement of development work.
Noumed's Australian Operations and Long-Term Contract Renewal
Noumed Pharmaceuticals, the company's Australian platform, renewed its exclusive OTC supply agreement with the EBOS Group for 7.5 years, valued at AUD 202 million (approximately Rs. 1,300 crore). This contract is designed for growth, with targets including the addition of 12 new products annually. The agreement provides predictable recurring revenue and strengthens Noumed's market position. Despite supply chain disruption🌐s from the West Asian situation in Q1, which led to elevated air freight costs, Noumed met its service level agreements by moving inventory via air, albeit at a cost to Q1 margins.
Australian Facility Development and US Market Entry Plans
The Australian facility is on schedule, with physical completion targeted for January 2027, TGA licensing inspection by March 2027, and Phase 1 manufacturing expected from April 2027. The company has infused AUD 1.75 million towards the remaining AUD 5 million required for the facility. Additionally, the Board approved the incorporation of a subsidiary in the United States to evaluate entry into the US market. This evaluation is in a preliminary stage, with further disclosures expected as developments unfold.
Debt Position and FY27 Outlook
As of June 30, 2026, the company's debt stood at Rs. 310 crores, a reduction of Rs. 10 crores from Rs. 319 crores in March 2026, following the repayment of Rs. 50 crores. Cash and cash equivalents were Rs. 184 crores. Management reiterated its FY27 guidance of Rs. 750 crores in revenue with an EBITDA margin of around 17%, noting that the year's revenue is weighted towards the second half⚖️ (45:55 split). The recovery of raw material cost benefits, partially realized in Q1, is expected to fully flow through the contract book in Q2, further supporting margin improvement.